Literature DB >> 28712978

Local Radiotherapy Intensification for Locally Advanced Non-small-cell Lung Cancer - A Call to Arms.

Noah S Kalman1, Elisabeth Weiss2, Paul R Walker3, Julian G Rosenman4.   

Abstract

Chemoradiotherapy, the standard of care for locally advanced non-small-cell lung cancer (NSCLC), often fails to eradicate all known disease. Despite advances in chemotherapeutic regimens, locally advanced NSCLC remains a difficult disease to treat, and locoregional failure remains common. Improved radiographic detection can identify patients at significant risk of locoregional failure after definitive treatment, and newer methods of escalating locoregional treatment may allow for improvements in locoregional control with acceptable toxicity. This review addresses critical issues in escalating local therapy, focusing on using serial positron emission tomography-computed tomography to select high-risk patients and employing stereotactic radiotherapy to intensify treatment. We further propose a clinical trial concept that incorporates the review's findings.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PET-CT; Serial imaging; Stage III lung cancer; Stereotactic body radiotherapy; Therapy escalation

Mesh:

Year:  2017        PMID: 28712978     DOI: 10.1016/j.cllc.2017.05.024

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  6 in total

Review 1.  Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer.

Authors:  Michael C Roach; Jeffrey D Bradley; Cliff G Robinson
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET/CT.

Authors:  Tineke W H Meijer; Robin Wijsman; Edwin A Usmanij; Olga C J Schuurbiers; Peter van Kollenburg; Liza Bouwmans; Johan Bussink; Lioe-Fee de Geus-Oei
Journal:  Phys Imaging Radiat Oncol       Date:  2018-08-31

3.  β-Elemene enhances radiosensitivity in non-small-cell lung cancer by inhibiting epithelial-mesenchymal transition and cancer stem cell traits via Prx-1/NF-kB/iNOS signaling pathway.

Authors:  Kun Zou; Zongjuan Li; Yang Zhang; Lin Mu; Miao Chen; Ruonan Wang; Wuguo Deng; Lijuan Zou; Jiwei Liu
Journal:  Aging (Albany NY)       Date:  2020-12-09       Impact factor: 5.682

4.  Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer.

Authors:  Qing Ma; Kai Geng; Ping Xiao; Lili Zeng
Journal:  Biomed Res Int       Date:  2021-09-02       Impact factor: 3.411

5.  Myeloid-Derived Suppressor Cells and CD68+CD163+M2-Like Macrophages as Therapeutic Response Biomarkers Are Associated with Plasma Inflammatory Cytokines: A Preliminary Study for Non-Small Cell Lung Cancer Patients in Radiotherapy.

Authors:  Minghe Lv; Xibing Zhuang; Shali Shao; Xuan Li; Yunfeng Cheng; Duojiao Wu; Xiangdong Wang; Tiankui Qiao
Journal:  J Immunol Res       Date:  2022-07-26       Impact factor: 4.493

6.  Analysis of Immunotherapy Combined with Radiotherapy in Patients with Brain Metastasis of Driver Gene-Negative Non-Small-Cell Lung Cancer.

Authors:  Qun Zhang; Shixiang Zhou; Hongmei Yin; Chaomang Zhu; Duojie Li; Xianming Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-23       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.